Cumulin and FSH Cooperate to Regulate Inhibin B and Activin B Production by Human Granulosa-Lutein Cells In Vitro.


Journal

Endocrinology
ISSN: 1945-7170
Titre abrégé: Endocrinology
Pays: United States
ID NLM: 0375040

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 05 12 2018
accepted: 01 02 2019
pubmed: 13 2 2019
medline: 18 12 2019
entrez: 13 2 2019
Statut: ppublish

Résumé

The oocyte-secreted factors bone morphogenetic protein 15 (BMP15) and growth differentiation factor 9 (GDF9) interact functionally, and it is hypothesized that this interaction may be mediated by formation of a GDF9:BMP15 heterodimer termed cumulin. GDF9 and BMP15 regulate folliculogenesis and ovulation rate and have been shown to regulate inhibin and activin, local regulators of folliculogenesis. The objective of this study was to determine whether cumulin regulates granulosa cell inhibin and activin production and whether this requires cooperation with FSH. Human granulosa-lutein (hGL) cells collected from patients undergoing in vitro fertilization were cultured with or without FSH with various forms of recombinant cumulin (native and cysteine mutants, with or without the prodomains), and cysteine mutant GDF9 or BMP15. Messenger RNA expression of the subunits of inhibins/activins (INHA, INHBA, INHBB) and secretion of inhibin A, inhibin B, and activin B were measured. Mature forms and proforms of cumulin stimulated comparable INHBB mRNA expression and secretion of inhibin B and activin B, whereas GDF9 or BMP15 exhibited no effect. Cumulin, but not GDF9 or BMP15, interacted synergistically with FSH to increase INHBB mRNA and inhibin B expression. FSH markedly stimulated INHA, which encodes the α subunit of inhibin A/B, and suppressed activin B. Cumulin with or without FSH did not significantly alter inhibin A. Together these data demonstrate that cumulin, but not GDF9 or BMP15, exerts paracrine control of FSH-induced regulation of inhibin B and activin B. The prodomains of cumulin may have a minimal role in its actions on granulosa cells.

Identifiants

pubmed: 30753406
pii: 5308413
doi: 10.1210/en.2018-01026
doi:

Substances chimiques

Bone Morphogenetic Protein 15 0
Chorionic Gonadotropin 0
Growth Differentiation Factor 9 0
activin B 0
inhibin B 0
Activins 104625-48-1
Inhibins 57285-09-3
Follicle Stimulating Hormone 9002-68-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

853-862

Informations de copyright

Copyright © 2019 Endocrine Society.

Auteurs

Dulama Richani (D)

Fertility & Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, Kensington, New South Wales, Australia.

Katherine Constance (K)

Fertility & Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, Kensington, New South Wales, Australia.

Shelly Lien (S)

Fertility & Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, Kensington, New South Wales, Australia.

David Agapiou (D)

Fertility & Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, Kensington, New South Wales, Australia.

William A Stocker (WA)

Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Department of Chemistry and Biotechnology, Swinburne University of Technology, Hawthorn, Victoria, Australia.

Mark P Hedger (MP)

Centre for Reproductive Health, Hudson Institute of Medical Research, Clayton, Victoria, Australia.

William L Ledger (WL)

Fertility & Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, Kensington, New South Wales, Australia.

Jeremy G Thompson (JG)

Robinson Research Institute, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.

David M Robertson (DM)

Fertility & Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, Kensington, New South Wales, Australia.

David G Mottershead (DG)

Robinson Research Institute, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
Institute for Science and Technology in Medicine, School of Pharmacy, Keele University, Newcastle-under-Lyme, United Kingdom.

Kelly L Walton (KL)

Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Craig A Harrison (CA)

Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Robert B Gilchrist (RB)

Fertility & Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, Kensington, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH